A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Latest Information Update: 06 May 2025
At a glance
- Drugs LY 4086940 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 06 May 2025 New trial record